FibroGen, Inc (NASDAQ:FGEN) had its target price lifted by Stifel Nicolaus from $38.00 to $80.00 in a research report sent to investors on Tuesday morning, Marketbeat.com reports. Stifel Nicolaus currently has a buy rating on the biopharmaceutical company’s stock.

FGEN has been the topic of a number of other research reports. Goldman Sachs Group, Inc. (The) lowered shares of FibroGen from a buy rating to a neutral rating and set a $31.00 price target on the stock. in a report on Friday, July 21st. BidaskClub lowered shares of FibroGen from a strong-buy rating to a buy rating in a report on Monday, July 31st. Zacks Investment Research lowered shares of FibroGen from a hold rating to a sell rating in a report on Monday, May 8th. Citigroup Inc. reissued a buy rating and issued a $48.00 price target on shares of FibroGen in a report on Monday, June 26th. Finally, William Blair reissued an outperform rating on shares of FibroGen in a report on Monday, June 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. FibroGen has a consensus rating of Buy and an average price target of $56.86.

Shares of FibroGen (NASDAQ FGEN) traded down 9.80% during mid-day trading on Tuesday, reaching $44.65. 1,493,204 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $33.32 and a 200 day moving average price of $27.67. FibroGen has a 52-week low of $15.60 and a 52-week high of $49.50. The firm’s market cap is $3.12 billion.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.01. The company had revenue of $29 million during the quarter, compared to the consensus estimate of $34.80 million. FibroGen had a negative return on equity of 71.32% and a negative net margin of 105.59%. Analysts forecast that FibroGen will post ($1.86) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “FibroGen, Inc (NASDAQ:FGEN) PT Raised to $80.00” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/09/fibrogen-inc-nasdaqfgen-pt-raised-to-80-00.html.

In other news, Director Kalevi Kurkijarvi sold 2,000 shares of the company’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $27.40, for a total value of $54,800.00. Following the completion of the sale, the director now owns 36,000 shares of the company’s stock, valued at approximately $986,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Toshinari Tamura sold 30,000 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $28.89, for a total transaction of $866,700.00. Following the completion of the sale, the director now directly owns 60,000 shares of the company’s stock, valued at approximately $1,733,400. The disclosure for this sale can be found here. Insiders sold a total of 404,974 shares of company stock valued at $12,515,438 in the last ninety days. 14.90% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. acquired a new stake in shares of FibroGen during the fourth quarter worth about $462,000. Norges Bank acquired a new stake in shares of FibroGen during the fourth quarter worth about $8,480,000. Teachers Advisors LLC boosted its stake in shares of FibroGen by 3.7% in the fourth quarter. Teachers Advisors LLC now owns 461,901 shares of the biopharmaceutical company’s stock worth $9,885,000 after buying an additional 16,544 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of FibroGen during the first quarter worth about $574,000. Finally, Capital Impact Advisors LLC boosted its stake in shares of FibroGen by 8.7% in the first quarter. Capital Impact Advisors LLC now owns 46,710 shares of the biopharmaceutical company’s stock worth $1,151,000 after buying an additional 3,727 shares during the period. 43.45% of the stock is owned by institutional investors.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.